We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current SKYE market cap is 10.17B. The company's latest EPS is USD -0.0474 and P/E is -270.25.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 152k |
| Operating Income | -6.63M | -6.29M | -7.85M | -18.31M | -34.74M |
| Net Income | 1.05M | -6.56M | -8.52M | -19.48M | -37.65M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 2M | 2.67M | 9.86M | 9.11M | 11.94M |
| Total Liabilities | 1.45M | 2.22M | 3.99M | 12.12M | 14.07M |
| Total Equity | 548k | 451k | 5.86M | -3.01M | -2.13M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -6.03M | -6.06M | -6.47M | -12.74M | -13.95M |
| Investing | N/A | -7k | -91k | 5.21M | 6.6M |
| Financing | 6.01M | 6.7M | 13.08M | -209k | 16.44M |
| Market Cap | 10.17B |
| Price to Earnings Ratio | -270.25 |
| Price to Sales Ratio | 64.05k |
| Price to Cash Ratio | 8.01k |
| Price to Book Ratio | -4.77k |
| Dividend Yield | - |
| Shares Outstanding | 794.25M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 37.79k |
| 52 Week Change | 279.56% |
| 52 Week High | 19.4099 |
| 52 Week Low | 1.44 |
| Spread (Intraday) | 0.11 (0.85%) |
| Company Name | Skye Bioscience Inc (QB) |
| Address |
701 s carson st carson city, nevada 89701 |
| Website | https://skyebioscience.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
